Delivery Order SPE2DB25D3201-SPE2DB25FNRWB

Award Date 3/19/25
Potential Completion Date 3/20/25
Potential Value $5.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,922.92, is a Firm Fixed Price Delivery Order for the supply of CATHFLO ACTIVASE 2 MG VIALS. The contract has an ultimate completion date of July 29, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award is a delivery order issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,778.51 firm fixed-price contract is for the procurement of CATHFLO ACTIVASE 2 MG VIALS, a medical product, with a period of performance through February 19, 2025. This contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant...
This federal contract award, valued at $9,796.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of CATHFLO ACTIVASE 2 MG VIALS, with a completion date of November 15, 2024. The contract is a Firm Fixed Price arrangement, and there is no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,679.87 delivery order contract is for the supply of CATHFLO ACTIVASE 2 MG VIALS, a pharmaceutical product. The award is not set aside and is a firm fixed-price contract type with a performance period ending on May 15, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
This federal contract award, valued at $61,695.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of 4564977738 ACTIVASE 100 MG VIALS, a critical medical product, to support military healthcare programs. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, a primary vehicle for providing a comprehensive range of pharmaceutical products...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of CATHFLO ACTIVASE 2 MG VIALS. The contract has a ceiling value of $22,802.68 and a period of performance through January 7, 2025. It is a Firm Fixed Price Delivery Order contract, with no set-aside designation. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price type, valued at $21,358.51 and running through October 2, 2023. The contract is for the supply of ACTIVASE 100 MG VIALS, a critical medical product. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the...
This federal contract award, issued by the Defense Logistics Agency (DLA), is a delivery order with a firm fixed price of $3,393.60 to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of CATHFLO ACTIVASE 2 MG VIALS, a medical product, with a period of performance through January 24, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) valued at $999,999,999 with the DLA Troop Support...
This federal contract award, valued at $5,429.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type, and has an ultimate completion date of January 16, 2025. The contract is for the procurement of CATHFLO ACTIVASE 2 MG VIALS, a critical medical commodity supporting the healthcare needs of military personnel, veterans, and other...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,141.52 Firm Fixed Price delivery order is for the supply of ACTIVASE 100 MG VIALS, a critical medical product. The contract has an ultimate completion date of October 25, 2024 and was awarded on October 24, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
  • SPE2DB25D3201
    Indefinite Delivery Contract
  • SPE2DB25D3201-SPE2DB25FNRWB
    Delivery Order

This federal contract award, valued at $5,429.76, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which does not have a set-aside designation, is a delivery order for the supply of CATHFLO ACTIVASE 2 MG VIALS, a medical product.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 6/18/25, 11:20 AM